16/10/2026
Astatine-211 is gaining attention as one of the most promising radionuclides in targeted alpha therapy. Join the first session of our Scientific Webinar Series and hear directly from renowned experts actively contributing to its development and clinical application:
🎤 Prof. Sherry Yennello - Cyclotron Institute Director, Texas A&M University
🎤 Prof. Federica Pisaneschi - Associate Professor, UTHealth Houston
🎤 Mario Malinconico - Scientific Leader, Comecer
Together, they will discuss the production, clinical development and future potential of At-211, sharing insights and real-world experience from the field.
đź“… November 9
đź•“ 9:00 AM CST (Houston) | 4:00 PM CET (Rome)
đź”— Register today: https://eu1.hubs.ly/H0z7Lj80